Skip to content

A Study on the Treatment of Stress-Induced Anxiety Disorders with Low-Frequency Combined Frequency Transcranial Magnetic Stimulation

A Study on the Treatment of Stress-Induced Anxiety Disorders with Low-Frequency Combined Frequency Transcranial Magnetic Stimulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129122
Enrollment
Unknown
Registered
2026-07-31
Start date
2022-06-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, dizziness, headache, insomnia, memory impairment

Interventions

Treatment group (Group A):Low-frequency combined transcranial magnetic stimulation
Control group (Group B):Pharmacotherapy

Sponsors

Baotou City Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18–65 years7) All participants consented to participation and signed an informed consent form; 2.Study subjects were patients with anxiety disorders or comorbid anxiety conditions induced by stress or psychological trauma; 3.Patients must be capable of independent decision-making, have no communication barriers, and be right-handed; 4.Patients with severe cardiovascular or cerebrovascular diseases were excluded; 5.Participants were screened using the GAD-7, PHQ-9, and VAS scales; only those with moderate to severe anxiety or comorbid anxiety conditions were enrolled; 6.All participants consented to participation and signed an informed consent form; 7.Participants were randomly assigned via digital randomization to either the treatment group (low-frequency combined transcranial magnetic stimulation + pharmacotherapy) or the control group (standard pharmacotherapy);

Exclusion criteria

Exclusion criteria: 1.Patients under 18 years of age, or 65 years older; 2.Patients with severe organic cardiac or cerebral diseases (those with severe arrhythmias, severe epilepsy, or unsatisfactory treatment responses); 3.Patients with severe mental disorders such as schizophrenia; 4.Patients with metallic foreign bodies in the body, including coronary stents or intracranial metal stents; 5.Patients without legal capacity or those with severe cognitive impairment; 6.Patients who refuse participation in the study; 7.Vulnerable populations.

Design outcomes

Primary

MeasureTime frame
GAD7;Hamilton Anxiety Scale score;VAS score;Efficacy assessment;

Secondary

MeasureTime frame
Lymphocyte subsets or LP-PLA2, etc.;

Countries

China

Contacts

Public ContactXiaoyan Liu

Baotou Central Hospital

2835365505@qq.com+86 472 6955201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026